Literature DB >> 16054571

Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment.

Judith V M G Bovée1, Anne-Marie Cleton-Jansen, Antonie H M Taminiau, Pancras C W Hogendoorn.   

Abstract

Chondrosarcoma is a malignant cartilage-forming tumour of bone, of which distinct clinicopathological subtypes are known. Conventional chondrosarcoma is notorious for its locally aggressive behaviour as well as for its resistance to chemotherapy and radiotherapy; so far surgery is the only effective therapeutic option. During the past 10 years, substantial new insights have been gained about molecular cell biology, molecular cytogenetics, and immunopathology, leading to better understanding of chondrosarcoma development at the molecular level, which will ultimately lead to better clinical understanding and possibly to the development of targeted treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16054571     DOI: 10.1016/S1470-2045(05)70282-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  51 in total

1.  Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients.

Authors:  Suzan H M Verdegaal; Judith V M G Bovée; Twinkal C Pansuriya; Robert J Grimer; Harzem Ozger; Paul C Jutte; Mikel San Julian; David J Biau; Ingrid C M van der Geest; Andreas Leithner; Arne Streitbürger; Frank M Klenke; Francois G Gouin; Domenico A Campanacci; Perrine Marec-Berard; Pancras C W Hogendoorn; Ronald Brand; Antonie H M Taminiau
Journal:  Oncologist       Date:  2011-12-06

Review 2.  Pathology of primary malignant bone and cartilage tumours.

Authors:  L B Rozeman; A M Cleton-Jansen; P C W Hogendoorn
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

Review 3.  Cartilage diseases.

Authors:  Yamini Krishnan; Alan J Grodzinsky
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

Review 4.  Has the Scottish Managed Clinical Network for Sarcoma influenced the survival outcomes for primary malignant bone tumours?

Authors:  F MacDonald; S Gupta
Journal:  J Orthop       Date:  2019-03-07

5.  Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Authors:  François A Simard; Iseulys Richert; Alexandra Vandermoeten; Anne-Valérie Decouvelaere; Jean-Philippe Michot; Christophe Caux; Jean-Yves Blay; Aurélie Dutour
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

6.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 7.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

8.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

9.  Malignant progression in two children with multiple osteochondromas.

Authors:  Gregory A Schmale; Douglas S Hawkins; Joe Rutledge; Ernest U Conrad
Journal:  Sarcoma       Date:  2010-05-09

10.  Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.

Authors:  Mandy Geryk-Hall; Dennis P M Hughes
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.